One week treatment with salmeterol does not prevent early and late asthmatic responses and Sputum eosinophilia induced by allergen challenge in asthmatics

Pulmonary Pharmacology and Therapeutics

Volumn 17, Issue 3, 2004, Pages 147-153

  Dente, F L ^a   Bacci, E ^a   Bartoli, M L ^a   Cianchetti, S ^a   Di Franco, A ^a   Giannini, D ^a   Taccola, M ^a   Vagaggini, B ^a   Paggiaro, P L ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Allergen bronchial challenge; DP, dermatophagoides pteronyssinus; EAR, early asthmatic response; Eosinophils; FEV1, forced expiratory volume in 1 s; Induced sputum; LAR, late asthmatic response; Long acting 2 agonists

Indexed keywords

ALLERGEN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; EOSINOPHIL CATIONIC PROTEIN; SALMETEROL;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; EOSINOPHILIA; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; SPUTUM; SPUTUM ANALYSIS; SPUTUM LEVEL; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHIAL PROVOCATION TESTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EOSINOPHILIA; FEMALE; HUMANS; MALE; SPUTUM;

EID: 1942486277     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pupt.2004.01.005     Document Type: Article

References (34)

1. 2-agonists in asthma treatment. 1997;179-195 Marcel Dekker, New York.
2. Twentyman O.P., Finnerty J.P., Harris A., Palmer J., Holgate S.T. Protection against allergen-induced asthma by salmeterol. Lancet. 336:1990;1338-1342.
3. Weersink A.J., Aalbers R., Koeter G.H., Kauffman H.F., De Monchy J.G., Postma D.S. Partial inhibition of the early and late asthmatic response by a single dose of salmeterol. Am J Respir Crit Care Med. 150:1994;1262-1267.
4. Dente F.L., Bancalari L., Bacci E., Bartoli M.L., Carnevali S., Cianchetti S., Di Franco A., Giannini D., Vagaggini B., Testi R., Paggiaro P.L. Effect of a single dose of salmeterol on the increase in airway eosinophils induced by allergen challenge in asthmatic subjects. Thorax. 54:1999;622-624.
5. O'Byrne P.M., Dolovich J., Hargreave F.E. State of art: late asthmatic response. Am Rev Respir Dis. 136:1987;740-751.
6. Woolley K.L., Adelroth E., Woolley M.J., Ellis R., Jordana M., O'Byrne P.M. Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. Am J Respir Crit Care Med. 151:1995;1915-1924.
7. 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 327:1992;1198-1203.
8. Ramage L., Lipworth B.J., Ingram C.G., Cree I.A., Dhillon D.P. Reduced protection against exercise-induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 88:1994;363-368.
9. Giannini D., Carletti A., Dente F.L., Bacci E., Di Franco A., Vagaggini B., Paggiaro P.L. Tolerance to the protective effect of salmeterol on allergen challenge. Chest. 110:1996;1452-1457.
10. Cockcroft D.W., McParland C.M., Britto S.A., Swystun V.A., Rutherford B.C. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet. 342:1993;833-837.
11. Boulet L.-P., Chakir J., Milot J., Boutet M., Laviolette M. Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma. Clin Exp Allergy. 31:2001;430-437.
12. Fahy J.V., Liu J., Wong H., Boushey H.A. Cellular and biochemical analysis of induced sputum from asthmatic and from healthy subjects. Am Rev Respir Dis. 147:1993;1126-1131.
13. Dente F.L., Bacci E., Di Franco A., Giannini D., Conti I., Macchioni P., Scoutri L., Taccola M., Vagaggini B., Paggiaro P.L. Reproducibility of early and late asthmatic responses to allergen challenge in a large group of asthmatics. Respir Med. 94:2000;441-447.
14. Pin I., Gibson P.G., Kolendowicz R., Girgis-Gabardo A., Denburg J.A., Hargreave F.E., Dolovich J. Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax. 47:1992;25-29.
15. Bacci E., Cianchetti S., Paggiaro P.L., Carnevali S., Bancalari L., Dente F.L., Di Franco A., Giannini D., Vagaggini B., Giuntini C. Comparison between hypertonic and isotonic saline-induced sputum in the evaluation of airway inflammation in subjects with moderate asthma. Clin Exp Allergy. 26:1996;1395-1400.
16. Bacci E., Cianchetti S., Carnevali S., Bartoli M.L., Dente F.L., Di Franco A., Giannini D., Vagaggini B., Paggiaro P.L. Induced sputum is a reproducible method to assess airway inflammation in asthma. Med Inflamm. 11:2002;293-298.
17. Ahlstedt S. Clinical application of eosinophil cationic protein in asthma. Allergy Proc. 16:1995;59-62.
18. Armitage P., Berry G. Statistical methods in medical research. 3rd ed. 1994;Blackwell Scientific Publications, Oxford.
19. 2-agonists and airway response to allergen. J Allergy Clin Immunol. 102:1998;S96-S99.
20. 2-agonists. Thorax. 51:1996;1051-1056.
21. Barnes P.J. Biology of respiratory tract receptors. Chung K.F., Barnes P.J. Pharmacology of the respiratory tract: experimental and clinical research. 1996;1-25 Marcel Dekker, New York.
22. Lotvall J., Lunde H., Tornqvist H., Tornqvist H., Svedmyr N. Twelve months treatment with inhaled salmeterol in asthmatic patients. Allergy. 47:1992;477-483.
23. Drotar D.E., Davis E.E., Cockcroft D.W. Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment. Ann Allergy Asthma Immunol. 80:1998;31-34.
24. Aziz I., Tan K.S., Hall I.P., Devlin M.M., Lipworth B.J. Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once daily formoterol. Eur Respir J. 12:1998;580-584.
25. 2-agonists. Is there cause concern? Drug Saf. 16:1997;295-308.
26. Whelan C.J., Johnson M. Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skin. Br J Pharmacol. 105:1992;831-838.
27. O'Connor B.J., Aikman S.L., Barnes P.J. Tolerance to nonbronchodilator effects of inhaled beta-agonists in asthma. N Engl J Med. 327:1992;1204-1208.
28. Rabe K.F., Giembycz M.A., Dent G., Perkins R.S., Evans P., Barnes P.J. Salmeterol is a competitive antagonist at β-adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. Eur J Pharmacol. 231:1993;305-308.
29. Gauvreau G.M., Jordana M., Watson R.M., Cockroft D.W., O'Byrne P.M. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med. 156:1997;1738-1745.
30. Giannini D., Di Franco A., Bacci E., Dente F.L., Vagaggini B., Taccola M., Tonelli M., Zingoni M., Paggiaro P. Tolerance to the protective effect of salmeterol in mild untreated asthmatics. Pulm Pharmacol Ther. 16:(6):2003;355-360.
31. 2-agonist treatment. Am Rev Respir Dis. 148:1993;707-712.
32. 2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J. 14:1999;275-282.
33. Taylor D.R., Town G.I., Herbison G.P., Boothman-Burrell D., Flannery E.M., Hancox B., Harre E., Laubscher K., Linscott V., Ramsay C.M., Richards G. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax. 53:1998;744-752.
34. National Institutes of Health. Global strategy for asthma management and prevention. NHLBI Workshop Report 1995. Publication No. 95-3659; January 1995.